UNCY
UNICYCIVE THERAPEUTICS, INC.
Company Overview
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
SectorHealthcare
IndustryBiotechnology
Market Cap$137.8M
Employees21
CEOShalabh K. Gupta
Websitehttps://www.unicycive.com
Valuation
Current Price$5.16
Fair Value?$000.00
Valuation?No valuation
Hist. PE ?N/Aⓘ
EPS (TTM) ?-1.31
Forward EPS Growth ?—
Historical Growth ?74.12%
Equity, FCF, Long Term Debt, Net Profit, and Shares Outstanding history charts are available on the Pro plan for just $9.99/month.Sign in to unlock Pro
Price
EPS
Revenue
Equity
ProAvailable on the Pro plan
Free Cash Flow
ProAvailable on the Pro plan
Long Term Debt
ProAvailable on the Pro plan
Net Profit
ProAvailable on the Pro plan
Shares Outstanding
ProAvailable on the Pro plan
Last updated: 9/5/2026, 6:58:04 PM